Palvella Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Palvella Therapeutics, Inc. (PVLA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $12.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-31
- Palvella Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $12.88M, a 83.32% decline from fiscal 2024.
- Palvella Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $77.24M.
- Palvella Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$4.74M, a 164.86% decline from fiscal 2022.
- Palvella Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $7.30M, a 23.16% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $12.88M 10-K · filed 2026-03-31 | |
| 2024-12-31 | $77.24M 10-K · filed 2026-03-31 | |
| 2023-12-31 | -$4.74M 10-K · filed 2025-03-31 | $11.90M 10-K · filed 2024-03-29 |
| 2022-12-31 | $7.30M 10-K · filed 2023-03-31 | |
| 2021-12-31 | $9.50M 10-K · filed 2022-03-02 | |
| 2020-12-31 | -$9.80M 10-K · filed 2021-03-31 | |
| 2019-12-31 | -$3.20M 10-K · filed 2020-03-13 | |
| 2018-12-31 | -$5.60M 10-K · filed 2019-03-18 | |
| 2017-12-31 | $5.50M 10-K · filed 2018-03-15 | |
| 2016-12-31 | $5.90M 10-K · filed 2017-03-30 | |
| 2014-12-31 | $7.14M 10-K · filed 2015-03-30 | |
| 2014-06-30 | -$5.43K 10-Q · filed 2014-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |